Mode of Transmission Affects the Sensitivity of Human Immunodeficiency Virus Type 1 to Restriction by Rhesus TRIM5α

ABSTRACT Rhesus TRIM5α (rhTRIM5α), but not human TRIM5α (huTRIM5α), potently inhibits human immunodeficiency virus (HIV) infection and is thus a potentially valuable therapeutic tool. Primary human CD4 T cells engineered to express rhTRIM5α were highly resistant to cell-free HIV type 1 (HIV-1) infection. However, when cocultured with unmodified T cells, rhTRIM5α-expressing cells became highly permissive to HIV-1 infection. Physical separation of rhTRIM5α-expressing cells and unmodified cells revealed that rhTRIM5α efficiently restricts cell-free but not cell-associated HIV transmission. Furthermore, we observed that HIV-infected human cells could infect rhesus CD4 T cells by cell-to-cell contact, but the infection was self-limiting. Subsequently, we noted that a spreading infection ensued when HIV-1-infected rhTRIM5α-expressing human cells were cultured with huTRIM5α- but not rhTRIM5α-expressing cells. Our results suggest that cell-associated HIV transmission in humans is blocked only when both donor and recipient cells express rhTRIM5α. These studies further define the role of rhTRIM5α in cell-free and cell-associated HIV transmission and delineate the utility of rhTRIM5α in anti-HIV therapy.

[1]  Q. Sattentau,et al.  Dangerous liaisons at the virological synapse. , 2004, The Journal of clinical investigation.

[2]  R. Akkina,et al.  TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  S. Nisole,et al.  TRIM family proteins: retroviral restriction and antiviral defence , 2005, Nature Reviews Microbiology.

[4]  D. Birx,et al.  Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection , 2002, Nature Medicine.

[5]  M. Yap,et al.  All Three Variable Regions of the TRIM5α B30.2 Domain Can Contribute to the Specificity of Retrovirus Restriction , 2006, Journal of Virology.

[6]  R. Tsien,et al.  A monomeric red fluorescent protein , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  R Blumenthal,et al.  Quantitation of human immunodeficiency virus type 1 infection kinetics , 1993, Journal of virology.

[8]  Jonathan P. Stoye,et al.  A Single Amino Acid Change in the SPRY Domain of Human Trim5α Leads to HIV-1 Restriction , 2005, Current Biology.

[9]  C. June,et al.  CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes 1 , 2003, The Journal of Immunology.

[10]  Claire Hivroz,et al.  ZAP‐70 kinase regulates HIV cell‐to‐cell spread and virological synapse formation , 2007, The EMBO journal.

[11]  Joseph Sodroski,et al.  Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Sodroski,et al.  Species-Specific Variation in the B30.2(SPRY) Domain of TRIM5α Determines the Potency of Human Immunodeficiency Virus Restriction , 2005, Journal of Virology.

[13]  Y. Takeuchi,et al.  Restriction of lentivirus in monkeys , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  John R. Mascola,et al.  Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.

[15]  E. Freed,et al.  Retrovirus budding. , 2004, Virus research.

[16]  J. Trowsdale,et al.  Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function , 2007, Proceedings of the National Academy of Sciences.

[17]  W. Mothes,et al.  Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission , 2007, Nature Cell Biology.

[18]  Smaroula Dilioglou,et al.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector , 2004, Nature Biotechnology.

[19]  V. Slepushkin,et al.  Safe two‐plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one‐step protocol , 2004, The journal of gene medicine.

[20]  T. Hope,et al.  Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Pérez-Caballero,et al.  No effect of endogenous TRIM5α on HIV-1 production , 2008, Nature Medicine.

[22]  S. Goff Genetic control of retrovirus susceptibility in mammalian cells. , 2004, Annual review of genetics.

[23]  S. O’Brien,et al.  Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for CCR5 Δ32 , 1998, Journal of Virology.

[24]  A. Engelman,et al.  Proteasome Inhibition Reveals that a Functional Preintegration Complex Intermediate Can Be Generated during Restriction by Diverse TRIM5 Proteins , 2006, Journal of Virology.

[25]  A. Haase,et al.  Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. , 1999, Annual review of immunology.

[26]  R. Akkina,et al.  Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. , 2008, Human gene therapy.

[27]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[28]  S. Anderson,et al.  The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 In Vitro , 1999, Journal of Virology.

[29]  S. Goff Retrovirus restriction factors. , 2004, Molecular cell.

[30]  C. June,et al.  Principles of adoptive T cell cancer therapy. , 2007, The Journal of clinical investigation.

[31]  Y. Ikeda,et al.  Rhesus monkey TRIM5α restricts HIV-1 production through rapid degradation of viral Gag polyproteins , 2007, Nature Medicine.

[32]  H. Fox,et al.  Trim5α Accelerates Degradation of Cytosolic Capsid Associated with Productive HIV-1 Entry* , 2006, Journal of Biological Chemistry.

[33]  T. Hope,et al.  Heat Shock Perturbs TRIM5α Restriction of Human Immunodeficiency Virus Type 1 , 2007, Journal of Virology.

[34]  Trushar R. Patel,et al.  Blockade of HIV-1 Infection of New World Monkey Cells Occurs Primarily at the Stage of Virus Entry , 2002, The Journal of experimental medicine.

[35]  A. Ishimoto,et al.  Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells , 1991, Journal of virology.

[36]  B. Levine,et al.  Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. , 1997, Science.

[37]  O. Schwartz,et al.  Inefficient Human Immunodeficiency Virus Replication in Mobile Lymphocytes , 2006, Journal of Virology.

[38]  Clare Jolly,et al.  HIV-1 Cell to Cell Transfer across an Env-induced, Actin-dependent Synapse , 2004, The Journal of experimental medicine.

[39]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[40]  Joseph Sodroski,et al.  Removal of Arginine 332 Allows Human TRIM5α To Bind Human Immunodeficiency Virus Capsids and To Restrict Infection , 2006, Journal of Virology.

[41]  S. Zolla-Pazner,et al.  Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage , 1998, Journal of Virology.

[42]  A. Fauci,et al.  Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. , 1989, Journal of immunology.